Back to Search Start Over

Leading Factors of Progression in Patients with Cardiac Amyloidosis

Authors :
A. S. Rameeva
V. V. Rameev
I. N. Bobkova
A. F. Safarova
Zh. D. Kobalava
S. V. Moiseev
Source :
Rational Pharmacotherapy in Cardiology. 18:143-152
Publication Year :
2022
Publisher :
Stolichnaya Izdatelskaya Kompaniyaizdat, 2022.

Abstract

Aim. To describe prognostic meaning of cardiac and other principal clinical manifestations of systemic AL-amyloidosis in their interrelations.Material and methods. It has been made long-time survival analysis of 147 patients with systemic AL-amyloidosis. In the special investigation group (n=58) of AL (n=55) and ATTR (n=3) amyloidotic cardiopathy patients there were evaluated prognostically important structural and functional changes in myocardium with standard and impulse-wave tissue dopplerometric echocardiography in comparison with NTproBNP serum levels.Results. Even though significantly increased nowadays surviving of AL-amylodotic patients (Me=90 months) it has been found that as at previously time orthostatic hypotension and amyloid cardiopathy are being most severe initial syndromes (median 25 months), but after 1 year from diagnosis influence of these syndromes on surviving had decreased and most low surviving was more common in patients with CKD 3-5 (median 28 months). Influence of CKD 3-5 on surviving was associated predominantly with intracardial hemodynamics deterioration. Together with decreased systolic shortening strain rate (48,5%) decreased filtration rate (47,9%) was second of main factors contributing into NTproBNP increasing in effective multiple regression model (R=0,702, F(4,21)=5,095, p=0,005). NTproBNP level in less degree depended on renal clearance.Conclusion. Heart damage is one of the most prognostically unfavorable manifestations of systemic amyloidosis due to a sharp deterioration in the elastic properties of the myocardium, in the process of further development of amyloidosis, the leading factor in progression is the deterioration of the profile of cardiorenal interactions, the marker of which is the level of NTproBNP.

Details

ISSN :
22253653 and 18196446
Volume :
18
Database :
OpenAIRE
Journal :
Rational Pharmacotherapy in Cardiology
Accession number :
edsair.doi...........e0df0217c45dfef33627610d0e72ffea